Loading
A phase 1 trial of ARX517 alone or with apalutamide or abiraterone in metastatic prostate cancer, run by Janssen Research & Development, LLC, active but no longer recruiting.
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer is a phase 1 interventional study registered as NCT04662580 by Janssen Research & Development, LLC; 183 participants are planned, it started on 2021-05-03; the registry gives 2026-12-31 as its primary completion date. Interventions recorded: ARX517, Apalutamide, Abiraterone acetate, Prednisone. Conditions listed: Metastatic Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Apalutamide, Abiraterone acetate, Prednisone, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Apalutamide, Abiraterone acetate, Prednisone, Johnson & Johnson and the tag pipeline.
Shares Apalutamide, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Apalutamide, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Apalutamide, Johnson & Johnson, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/